Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Zhang

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Antimicrobial Agents and Chemotherapy|December 15, 2023
Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171Hong Zhang, Jing Zhou, Hong Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 28, 2006
Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81J George Zhang, Shangara S Dehal, Thuy Ho, et al.
Virology Journal|December 20, 2024
Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled designMin Wu, Jiajia Mai, Hong Zhang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 25, 2009
Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cellsDermot F McGinnity, George Zhang, Jane R Kenny, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 14, 2014
Evaluation of calibration curve-based approaches to predict clinical inducers and noninducers of CYP3A4 with plated human hepatocytesJ George Zhang, Thuy Ho, Alanna L Callendrello, et al.
Thrombosis and Haemostasis|February 8, 2019
Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTEStefano Barco, Serena Granziera, Michiel Coppens, et al.
Nature Genetics|September 19, 2006
Cranio-lenticulo-sutural dysplasia is caused by a SEC23A mutation leading to abnormal endoplasmic-reticulum-to-Golgi traffickingSimeon A Boyadjiev, J Christopher Fromme, Jin Ben, et al.
Thrombosis and Haemostasis|July 22, 2016
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trialPeter Verhamme, Philip S Wells, Annelise Segers, et al.
Bioorganic & Medicinal Chemistry Letters|August 29, 2006
Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3Jack J Chen, Kumar D Thakur, Michael P Clark, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 3, 2020
Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro Cytochrome P450 Induction Studies Including Impact on Drug Interaction Risk AssessmentSimon G Wong, Diane Ramsden, Shannon Dallas, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Antimicrobial Agents and Chemotherapy|December 15, 2023
Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171Hong Zhang, Jing Zhou, Hong Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 28, 2006
Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81J George Zhang, Shangara S Dehal, Thuy Ho, et al.
Virology Journal|December 20, 2024
Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled designMin Wu, Jiajia Mai, Hong Zhang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 25, 2009
Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cellsDermot F McGinnity, George Zhang, Jane R Kenny, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 14, 2014
Evaluation of calibration curve-based approaches to predict clinical inducers and noninducers of CYP3A4 with plated human hepatocytesJ George Zhang, Thuy Ho, Alanna L Callendrello, et al.
Thrombosis and Haemostasis|February 8, 2019
Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTEStefano Barco, Serena Granziera, Michiel Coppens, et al.
Nature Genetics|September 19, 2006
Cranio-lenticulo-sutural dysplasia is caused by a SEC23A mutation leading to abnormal endoplasmic-reticulum-to-Golgi traffickingSimeon A Boyadjiev, J Christopher Fromme, Jin Ben, et al.
Thrombosis and Haemostasis|July 22, 2016
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trialPeter Verhamme, Philip S Wells, Annelise Segers, et al.
Bioorganic & Medicinal Chemistry Letters|August 29, 2006
Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3Jack J Chen, Kumar D Thakur, Michael P Clark, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 3, 2020
Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro Cytochrome P450 Induction Studies Including Impact on Drug Interaction Risk AssessmentSimon G Wong, Diane Ramsden, Shannon Dallas, et al.
Pageof 8